With shares sitting 73% into the red in 2021, it’s safe to say, Chemocentryx (CCXI) investors have endured a difficult year so far. The alarming decline has mostly been due to one event; in May, an FDA advisory committee expressed reservations regarding the application for avacopan, Chemocentryx’ treatment for anti-neutrophilic cytoplasmic autoantibody (ANCA)-vasculitis (AAV) – a rare disorder which can lead to inflammation and even destruction of small blood vessels.  On Tuesday, however, the company had some positive news concerning the drug.
https://www.tipranks.com/news/article/chemocentryx-a-risky-yet-potentially-lucrative-bet
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more ChemoCentryx Charts.
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more ChemoCentryx Charts.